Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
暂无分享,去创建一个
Philippe Brouqui | Philippe Colson | Jean-Marc Rolain | Didier Raoult | Jean-Christophe Lagier | D. Raoult | P. Brouqui | J. Rolain | P. Colson | J. Lagier | D. Raoult
[1] T. Bestebroer,et al. Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture , 2014, Antimicrobial Agents and Chemotherapy.
[2] I. Spyridopoulos,et al. Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery , 2020, Hellenic Journal of Cardiology.
[3] D. Raoult,et al. Azithromycin Inhibits the Replication of Zika Virus , 2018 .
[4] P. Maes,et al. Antiviral Activity of Chloroquine against Human Coronavirus OC43 Infection in Newborn Mice , 2009, Antimicrobial Agents and Chemotherapy.
[5] D. Raoult,et al. Treatment of classic Whipple's disease: from in vitro results to clinical outcome. , 2014, The Journal of antimicrobial chemotherapy.
[6] D. Raoult,et al. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century , 2007, International Journal of Antimicrobial Agents.
[7] Science multicenter collaboration group of Department of,et al. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.
[8] D. Raoult,et al. Bactericidal effect of doxycycline associated with lysosomotropic agents on Coxiella burnetii in P388D1 cells , 1990, Antimicrobial Agents and Chemotherapy.
[9] Jianjun Gao,et al. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.
[10] H. Shirasawa,et al. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: Involvement of p38 MAPK and ERK , 2007, Antiviral Research.
[11] E. De Clercq,et al. Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. , 2006, Journal of medicinal chemistry.
[12] Marc Van Ranst,et al. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine , 2004, Biochemical and Biophysical Research Communications.
[13] D. Barnard,et al. Evaluation of Immunomodulators, Interferons and Known in Vitro SARS-CoV Inhibitors for Inhibition of SARS-Cov Replication in BALB/c Mice , 2006, Antiviral chemistry & chemotherapy.
[14] Wu Zhong,et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro , 2020, Cell Research.
[15] F. Fenollar,et al. Whipple's disease. , 2007, The New England journal of medicine.
[16] Philippe Colson,et al. Chloroquine for the 2019 novel coronavirus SARS-CoV-2 , 2020, International Journal of Antimicrobial Agents.
[17] N. Seidah,et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.
[18] T. Takano,et al. Effect of chloroquine on feline infectious peritonitis virus infection in vitro and in vivo , 2013, Antiviral Research.
[19] Md Abdul Alim Al-Bari,et al. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases , 2015, The Journal of antimicrobial chemotherapy.
[20] Sukhdev Singh,et al. COVID-19: The Case of Three Patients with the Same Diagnosis but Different Clinical and Laboratory Features , 2020, Case reports in medicine.
[21] Kazi Faizul Azim,et al. Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach , 2020, Informatics in Medicine Unlocked.
[22] D. Raoult,et al. Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine. , 1999, Archives of internal medicine.
[23] Jean-Marc Rolain,et al. Antibiotic Susceptibility of Tropheryma whipplei in MRC5 Cells , 2004, Antimicrobial Agents and Chemotherapy.
[24] M. Toumi,et al. Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al , 2020, Journal of market access & health policy.
[25] Roberto Cauda,et al. New insights into the antiviral effects of chloroquine , 2006, The Lancet Infectious Diseases.
[26] A. Sposito,et al. Diacerein: A potential multi-target therapeutic drug for COVID-19 , 2020, Medical Hypotheses.